Literature DB >> 28440499

Effects of tanshinone IIA on the regulation of renal proximal tubular fibrosis.

Luoyuan Cao1, Baoying Huang1, Xianguo Fu1, Jing Yang1, Yinghua Lin1, Feng Lin1.   

Abstract

The development of diabetes mellitus, along with its complications, is a chronic inflammatory response process. Chronic kidney diseases are characterized by renal fibrosis, and fibrosis is an important pathway for end‑stage renal failure. According to previous studies, high glucose (HG) has been demonstrated to be the most important fibrogenesis‑inducing agent. Tanshinone IIA is one of the main components isolated from Danshen (Salvia miltiorrhiza). Although tanshinone IIA has been widely used for the treatment of cardiovascular diseases, the possible role of tanshinone IIA in fibrosis regulation remains to be elucidated and requires investigation. In the present study, renal proximal tubular epithelial cells (HK‑2) were treated with HG (30 mM glucose) to determine whether tanshinone IIA (1, 10 and 50 µM) had an effect on the regulation of renal cellular fibrosis. The results demonstrated that 50 µM tanshinone IIA may exert optimal inhibitory effects on HG‑induced Snail, fibronectin, vimentin and α‑smooth muscle actin (α‑SMA) expression in HK‑2 cells after 48 h. Tanshinone IIA also reversed HG‑induced morphological alterations in HK‑2 cells and inhibited an HG‑induced increase in fibronectin and α‑SMA mRNA and protein and an HG‑induced decrease in E‑cadherin. Furthermore, tanshinone IIA suppressed an HG‑induced increase in Snail, which is a transcription factor that can suppress E‑cadherin expression. E‑cadherin is a major component of adherens junctions and a characteristic of epithelial integrity. Tanshinone IIA reversed HG‑induced increase in α‑SMA and decrease in E‑cadherin. These data suggest that tanshinone IIA has the potential to inhibit HG‑induced renal tubular epithelial cell fibrosis possibly through the epithelial‑myofibroblast transdifferentiation pathway. Therefore, tanshinone IIA may be considered a renoprotective agent for the treatment of renal fibrosis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28440499     DOI: 10.3892/mmr.2017.6498

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  5 in total

1.  Tanshinone IIA down-regulates -transforming growth factor beta 1 to relieve renal tubular epithelial cell inflammation and pyroptosis caused by high glucose.

Authors:  Ying Li; Xu Deng; Wenlong Zhuang; Yong Li; Hui Xue; Xin Lv; Shuqin Zhu
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

2.  Efficacy and Safety of Sodium Tanshinone IIA Sulfonate Injection on Hypertensive Nephropathy: A Systematic Review and Meta-Analysis.

Authors:  Junyao Xu; Chenghua Zhang; Xiaoqing Shi; Jie Li; Ming Liu; Weimin Jiang; Zhuyuan Fang
Journal:  Front Pharmacol       Date:  2019-12-24       Impact factor: 5.810

3.  Tanshinone IIA Ameliorates Streptozotocin-Induced Diabetic Nephropathy, Partly by Attenuating PERK Pathway-Induced Fibrosis.

Authors:  Shujuan Xu; Lianjun He; Keke Ding; Lingling Zhang; Xinhui Xu; Sheng Wang; Xueyi Qian
Journal:  Drug Des Devel Ther       Date:  2020-12-31       Impact factor: 4.162

Review 4.  Salvia miltiorrhiza in thorax and abdomainal organ fibrosis: A review of its pharmacology.

Authors:  Zhao Yang; Jingshu Qi; Dabing Ping; Xin Sun; Yanyan Tao; Chenghai Liu; Yuan Peng
Journal:  Front Pharmacol       Date:  2022-09-20       Impact factor: 5.988

5.  Tanshinone IIA reduces SW837 colorectal cancer cell viability via the promotion of mitochondrial fission by activating JNK-Mff signaling pathways.

Authors:  Sayilaxi Jieensinue; Hong Zhu; Guangcheng Li; Keli Dong; Meiting Liang; Yayue Li
Journal:  BMC Cell Biol       Date:  2018-09-25       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.